Cefalexin monohydrate 500mg equivalent to Cephalexin 500 mg - paieškos rezultatas

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

cefalexin 500mg capsules

sigma pharmaceuticals plc - cefalexin - oral capsule - 500mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

cefalexin 500mg capsules

mawdsley-brooks & company ltd - cefalexin - oral capsule - 500mg

Australija - anglų - Department of Health (Therapeutic Goods Administration)

apo-cephalexin (as monohydrate) 250mg capsule blister pack

arrotex pharmaceuticals pty ltd - cefalexin monohydrate, quantity: 275 mg (equivalent: cefalexin, qty 250 mg) - capsule, hard - excipient ingredients: sunset yellow fcf; lactose monohydrate; iron oxide yellow; titanium dioxide; magnesium stearate; gelatin; brilliant blue fcf; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections - caused by s. pneumoniae and group a b-haemolytic streptococci. (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present). bacterial sinusitis - caused by streptococci, s. pneumoniae and s aureus (methicillin sensitive only). otitis media - due to s. pneumoniae, staphylococci; skin and skin structure infections - caused by staphylococci and/or streptococci; genitourinary tract infections, including acute prostatitis - caused by e. coli, p. mirabilis and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and cephalexin is not indicated in these conditions. note:- appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to cephalexin. renal function studies should be performed when indicated.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

ibilex 500 cefalexin 500mg capsule blister pack

alphapharm pty ltd - cefalexin monohydrate, quantity: 526 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: titanium dioxide; quinoline yellow; gelatin; magnesium stearate; patent blue v; dimeticone 350; microcrystalline cellulose; carmellose sodium - indications as at 24 february 2004: ibilex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ibilex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of ibilex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of ibilex in the treatment of bacterial infections of the brain and spinal column has not been established and ibilex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to ibilex. renal function studies should be performed when indicated

Australija - anglų - Department of Health (Therapeutic Goods Administration)

ibilex 250 cefalexin 250mg capsule blister pack

alphapharm pty ltd - cefalexin monohydrate, quantity: 263 mg (equivalent: cefalexin, qty 250 mg) - capsule, hard - excipient ingredients: gelatin; dimeticone 350; magnesium stearate; titanium dioxide; patent blue v; quinoline yellow; microcrystalline cellulose; carmellose sodium - indications as at 24 february 2004: ibilex is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by s. pneumoniae and group a beta-haemolytic streptococci (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ibilex is generally effective in the eradication of streptococci from nasopharynx; however, substantial data establishing the efficacy of ibilex in the subsequent prevention of rheumatic fever are not available at present.) bacterial sinusitis caused by streptococci, s. pneumoniae and s. aureus (methicillin-sensitive only) otitis media due to s. pneumoniae, staphylococci; skin and soft tissue infections caused by staphlococci anr/or streptococci; genitourinary tract infections, including acute prostatic caused by e. coli, p. mirabilis, and klebsiella sp. the effectiveness of ibilex in the treatment of bacterial infections of the brain and spinal column has not been established and ibilex is not indicated in these conditions. note: appropriate culture and susceptibility test should be initiated prior to and during therapy to determine susceptibility of the causative organism to ibilex. renal function studies should be performed when indicated

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

cefalexin 500mg capsules

flynn pharma ltd - cefalexin - oral capsule - 500mg